Dapagliflozin, a SGLT2 inhibitor and sirtinol, a SIRT1 inhibitor, were used to investigate the role of the SGLT2-SIRT1 pathway in AF in a streptozotocin (STZ)-induced diabetes mellitus [121]. This evidence concerns the gene SLC5A2 and atrial fibrillation.